Less Ads, More Data, More Tools Register for FREE

Pin to quick picksZotefoams Plc Regulatory News (ZTF)

Share Price Information for Zotefoams Plc (ZTF)

Share Price is delayed by 15 minutes
Get Live Data
433.00    3.00 (0.70%)
Bid:
431.00
Ask:
433.50
Spread: 2.50 (0.58%)
Market Cap: £212.96m
ZTF Live PriceLast checked at - London Stock Exchange

Intraday Zotefoams Plc Share Chart

Trading Update

15 Dec 2022 07:00

RNS Number : 7596J
Zotefoams PLC
15 December 2022
 

Zotefoams plc

("Zotefoams" or "Group" or "Company")

 

Trading Update

Continued positive momentum through Q4 and full year profit ahead of market expectations

 

15 December 2022 - Zotefoams, a world leader in cellular materials technology, today provides an update in respect of its financial year ending 31 December 2022.

As communicated in the Group's trading update of 13 October, performance over the nine months to 30 September 2022 had been strong, with revenues approximately 24% ahead of the comparable prior year period. 

Encouragingly, trading during October and November has remained strong, with both the Polyolefin Foams and High-Performance Products businesses continuing to deliver year-on-year growth as well as a continued focus on cost and efficiency. As a result, based on current FX rates, the Board now expects Group FY22 adjusted profit before income tax to be ahead of current market expectations*, with the extent of the outperformance primarily dependent on the timing of customer shipments in the final weeks of the year.

Cash generation also continues to be positive. The better than anticipated earnings performance should contribute to an appreciable reduction in leverage compared with that reported in the interims at 30 June 2022. 

Commenting on the update David Stirling, Group CEO of Zotefoams, said: 

"I am pleased that Zotefoams continues to perform well and deliver excellent growth in both revenue and profitability. Whilst this year has seen considerable challenges in the form of both cost and demand volatility, we have continued to demonstrate resilience in mitigating these, which is testament to Zotefoams' well-established products and experienced team.

"Whilst we expect a number of the challenges experienced this year to continue into 2023, we are confident in our ability to respond and we continue to see significant opportunity for the Group."

 

* Current Company-compiled consensus expectations for adjusted profit before income tax and separately disclosed items, for the year ending 31 December 2022, is £10.7m.

 

 

- Ends -

 

Enquiries:

 

Zotefoams plc

+44 (0) 208 664 1600

David Stirling, Group CEO

Gary McGrath, Group CFO

IFC Advisory

+44 (0) 203 934 6630

Graham Herring

Tim Metcalfe

Zach Cohen

 

About Zotefoams plc

Zotefoams plc (LSE - ZTF) is a world leader in cellular materials technology delivering optimal material solutions for the benefit of society. Utilising a variety of unique manufacturing processes, including environmentally friendly nitrogen expansion for lightweight AZOTE® polyolefin and ZOTEK® high-performance foams, Zotefoams sells to diverse markets worldwide. Zotefoams uses its own cellular materials to manufacture T-FIT® advanced insulation for demanding industrial markets. Zotefoams also owns and licenses patented microcellular foam technology to reduce plastic use in extrusion applications and for ReZorce® mono-material recyclable barrier packaging.

Zotefoams is headquartered in Croydon, UK, with additional manufacturing sites in Kentucky, USA and Brzeg, Poland (foam manufacture), Oklahoma, USA (foam products manufacture and conversion), Massachusetts, USA (MuCell Extrusion) and Jiangsu Province, China (T-FIT).

www.zotefoams.com

AZOTE®, ZOTEK®, ReZorce® and T-FIT® are registered trademarks of Zotefoams plc.

www.zotefoams.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTZZMMZRDKGZZM
Date   Source Headline
6th Aug 20137:00 amRNSHalf Yearly Report
12th Jul 20139:29 amRNSJoint Venture in Asia
8th Jul 20137:00 amRNSTrading Update
3rd Jun 201311:37 amRNSDirector/PDMR Shareholding
21st May 20139:43 amRNSDirector/PDMR Shareholding
15th May 201312:02 pmRNSResult of AGM
15th May 20137:00 amRNSAGM Statement and Interim Management Statement
29th Apr 20134:27 pmRNSDirector/PDMR Shareholding
10th Apr 20135:45 pmRNS2012 Annual Report and Accounts and AGM Notice
10th Apr 20132:22 pmRNSHolding(s) in Company (Replacement)
26th Mar 20131:01 pmRNSHolding(s) in Company
19th Mar 20135:43 pmRNSDirector/PDMR Shareholding
19th Mar 20135:40 pmRNSDirector/PDMR Shareholding
15th Mar 201310:00 amRNSHolding(s) in Company
12th Mar 20139:19 amRNSDirector/PDMR Shareholding
5th Mar 20137:00 amRNSFinal Results
18th Feb 20133:14 pmRNSChange of Advisers
9th Jan 20137:00 amRNSTrading Update
14th Nov 20129:56 amRNSDirector Declaration
26th Oct 20127:00 amRNSInterim Management Statement
14th Aug 201211:58 amRNSNotification of Major Interest in shares
14th Aug 20127:00 amRNSMuCell Extrusion LLC Obtains an Exclusive License
7th Aug 20127:02 amRNSHalf Yearly Report
7th Aug 20127:00 amRNSDow and MuCell Extrusion LLC Enter Agreement
9th Jul 20127:00 amRNSTrading Update
12th Jun 201212:15 pmRNSDirector/PDMR Shareholding
10th May 201212:08 pmRNSResult of AGM
10th May 20127:00 amRNSAGM and Interim Management Statement
13th Apr 201212:31 pmRNSHolding(s) in Company
13th Apr 201210:43 amRNSDirector/PDMR Shareholding
5th Apr 20123:25 pmRNSAnnual Information Update
5th Apr 201212:23 pmRNS2011 Annual Report & Accounts and Notice of AGM
5th Apr 201210:31 amRNSDirector/PDMR Shareholding
28th Mar 20128:43 amRNSHolding(s) in Company
6th Mar 20127:00 amRNSFinal Results
27th Jan 201210:57 amRNSHolding(s) in Company
19th Jan 20124:48 pmRNSHolding(s) in Company
9th Jan 20127:00 amRNSTrading Statement
13th Dec 20113:27 pmRNSDirector/PDMR Shareholding
22nd Nov 20117:00 amRNSDirector/PDMR Shareholding
28th Oct 20112:18 pmRNSHolding(s) in Company
24th Oct 20117:00 amRNSInterim Management Statement
16th Sep 20112:35 pmRNSHolding(s) in Company
2nd Aug 20117:00 amRNSHalf Yearly Report
5th Jul 20117:00 amRNSTrading Update
16th Jun 20117:00 amRNSDirectorate Appointments
7th Jun 20119:13 amRNSAnnual Information Update
13th May 20112:10 pmRNSHolding(s) in Company
13th May 201110:34 amRNSResult of AGM
12th May 20117:00 amRNSAGM Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.